| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Pipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extra pyramidal reactions. It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation. |
| Indication |
For the maintenance treatment of chronic non-agitated schizophrenic patients. |
| Pharmacology |
Pipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extra pyramidal reactions. It reduces activity of dopamine receptors in the limbic system. Its 5-HT antagonism helps normalize dopamine activity in the cortical regions. |
| Toxicity |
Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation. |
| Affected Organisms |
| • |
Humans and other mammals |
|